Nephrol Dial Transplant (2000) 15: 1913-1916
© 2000 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
Lymphoproliferative disease post-renal transplantation
Department of Renal Medicine, St James's University Hospital, Beckett Street, Leeds, UK
Introduction
Solid organ transplant recipients are at a greatly increased risk of lymphoproliferative tumours. The majority is of B cell origin and has been shown to contain the Epstein–Barr virus (EBV) genome and express viral proteins on the cell surface. The virus attaches to the C3d complement component receptor so effects are confined to cells that carry this receptor. These are squamous epithelial cells of the oropharynx and B-lymphocytes. In the latter cell a latent infection occurs. The virus has the capability of transforming these cells into continuously growing immortalized lymphoblastoid lines.
Incidence and risk factors
The incidence of post-transplant lymphoproliferative disease (PTLD) in renal transplant recipients is of the order of 1% [1]: a risk of lymphoma approximately twenty times greater than that seen in the general population. The major risk factor for PTLD in solid organ transplantation is the degree of immunosuppression. A high incidence of PTLD was seen following the
The modes of clinical presentation
Managing the patient with PTLD
Conclusion
Notes
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. D. Hohenwalter, C. J. Skowlund, S. J. Erickson, S. Hariharan, W. S. Rilling, M. R. Crain, and P. Drescher Renal Transplant Evaluation with MR Angiography and MR Imaging RadioGraphics, November 1, 2001; 21(6): 1505 - 1517. [Abstract] [Full Text] [PDF]
|
|